ENTX
Entera Bio Ltd (ENTX)
Healthcare • NASDAQ • $1.30-5.11%
- Symbol
- ENTX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.30
- Daily Change
- -5.11%
- Market Cap
- $70.79M
- Trailing P/E
- N/A
- Forward P/E
- -2.36
- 52W High
- $3.22
- 52W Low
- $0.91
- Analyst Target
- $9.00
- Dividend Yield
- N/A
- Beta
- 1.55
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient…
Company websiteResearch ENTX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.